Alphabet Inc. Denali Therapeutics Inc. Transaction History

Alphabet Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2022	SELL	$12.46 - $21.74 $6.68 Million - $11.7 Million	-536,411 Closed	0 $0
Q2 2018 Nov 14, 2022	SELL	$15.25 - $21.02 $461,388 - $635,960	-30,255 Reduced 5.34%	536,411 $8.18 Million
Q4 2017 Nov 14, 2022	BUY	$15.04 - $21.45 $8.52 Million - $12.2 Million	566,666	566,666 $8.86 Million

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.81B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Alphabet Inc., based on Form 13F filings with the SEC.

Stay updated on Alphabet Inc. with notifications on news.